Chronic pulmonary mucormycosis caused by rhizopus microsporus mimics lung carcinoma in an immunocompetent adult: A case report

Guo, Xufeng; Gong, Liang-Hui; Wang, Wenxiang; Yang, Desong; Zhang, Baihua; Zhou, Ze-Tao; Yu, Xiaohui

doi:10.12998/wjcc.v11.i14.3295

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although certain Rhizopus species have long history in food preparation (e.g., Tempeh or starch liquefaction) thus considered safe in general (Hachmeister & Fung, 1993), not all species are safe for consumption. Recent studies within the past 5 years have highlighted the ability of Rhizopus species to induce chronic mucormycosis in various anatomical sites, including the lungs, gastrointestinal tract, and skin (Guo et al, 2023;Ukoha & Nguyen, 2021;Yuan et al, 2021;Zurl et al, 2021). The Rhizopus species are particularly implicated as the leading cause of pulmonary mucormycosis, a rare fungal infection primarily affecting individuals with poorly controlled diabetes or compromised immune systems.…”

Section: Safetymentioning

confidence: 99%

Mycoproteins and their health‐promoting properties: Fusarium species and beyond

Lee,

Pan,

Kim

et al. 2024

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Filamentous fungal mycoproteins have gained increasing attention as sustainable alternatives to animal and plant‐based proteins. This comprehensive review summarizes the nutritional characteristics, toxicological aspects, and health‐promoting effects of mycoproteins, focusing on those derived from filamentous fungi, notably Fusarium venenatum. Mycoproteins are characterized by their high protein content, and they have a superior essential amino acid profile compared to soybeans indicating excellent protein quality and benefits for human nutrition. Additionally, mycoproteins offer enhanced digestibility, further highlighting their suitability as a protein source. Furthermore, mycoproteins are rich in dietary fibers, which have been associated with health benefits, including protection against metabolic diseases. Moreover, their fatty acids profile, with significant proportions of polyunsaturated fatty acids and absence of cholesterol, distinguishes them from animal‐derived proteins. In conclusion, the future of mycoproteins as a health‐promoting protein alternative and the development of functional foods relies on several key aspects. These include improving the acceptance of mycoproteins, conducting further research into their mechanisms of action, addressing consumer preferences and perceptions, and ensuring safety and regulatory compliance. To fully unlock the potential of mycoproteins and meet the evolving needs of a health‐conscious society, continuous interdisciplinary research, collaboration among stakeholders, and proactive engagement with consumers will be vital.

show abstract

Section: Safetymentioning

confidence: 99%

Mycoproteins and their health‐promoting properties: Fusarium species and beyond

Lee,

Pan,

Kim

et al. 2024

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

show abstract

“…Such symptoms are also found in association with arterial aneurysms, pseudoaneurysms, and isolated cavernous lesions [ 7 ]. There have also been reports of PM mimicking a lung tumor [ 8 , 9 ]. The infection tends to be fatal without timely diagnosis and treatment and its mortality rate is reported to be over 50% [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review

Leng,

Zhou,

et al. 2024

JoF

View full text Add to dashboard Cite

Pulmonary mucormycosis (PM) is an invasive and potentially fatal fungal infection, with Rhizopus microsporus (R. microsporus) being the most common pathogen. The routine therapy for this infection includes surgery and antifungal agents. However, the therapeutic effects of single agents are unsatisfactory due to the rapid progression of mucormycosis, while not all patients can tolerate surgery. Innovative treatment methods like combination therapy await validations of their clinical efficacy. We report a case of PM that was diagnosed via metagenomics next-generation sequencing (mNGS) of black drainage fluid from the patient’s lung. The patient eventually recovered and was discharged after a combination therapy of oral isavuconazole, inhaled amphotericin B, and local perfusion of amphotericin B through bronchoscopy, which may be a promising strategy for the treatment of PM, especially for cases where surgery is not possible. A retrospective study of 297 cases in a literature review highlights the different treatment methods used in clinical practice.

show abstract

Chronic pulmonary mucormycosis caused by rhizopus microsporus mimics lung carcinoma in an immunocompetent adult: A case report

Cited by 2 publications

References 22 publications

Mycoproteins and their health‐promoting properties: Fusarium species and beyond

Mycoproteins and their health‐promoting properties: Fusarium species and beyond

Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review

Contact Info

Product

Resources

About